Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Selecta Biosciences, Inc. SELB
$1.15
-$0.05 (-4.58%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
183345275.00000000
-
week52high
2.73
-
week52low
0.67
-
Revenue
110777000
-
P/E TTM
3
-
Beta
1.17128000
-
EPS
0.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 21 июн 2022 г. |
| Needham | Buy | Buy | 14 июн 2022 г. |
| SVB Leerink | Outperform | 06 июн 2022 г. | |
| Needham | Buy | Buy | 06 мая 2022 г. |
| Needham | Buy | Buy | 01 ноя 2021 г. |
| Canaccord Genuity | Buy | Buy | 31 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| TRABER PETER G | D | 446121 | 20 | 05 янв 2023 г. |
| TRABER PETER G | D | 446141 | 3445 | 05 янв 2023 г. |
| Kishimoto Takashi Kei | D | 364316 | 20 | 05 янв 2023 г. |
| Kishimoto Takashi Kei | D | 364336 | 3372 | 05 янв 2023 г. |
| Johnston Lloyd P. | D | 265515 | 20 | 05 янв 2023 г. |
| Johnston Lloyd P. | D | 265535 | 3372 | 05 янв 2023 г. |
| Brunn Carsten | D | 786013 | 77 | 05 янв 2023 г. |
| Brunn Carsten | D | 786090 | 13396 | 05 янв 2023 г. |
| TRABER PETER G | D | 449586 | 15 | 04 янв 2023 г. |
| TRABER PETER G | D | 449601 | 8164 | 04 янв 2023 г. |
Новостная лента
Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 19:06
Selecta Biosciences, Inc. (NASDAQ:SELB ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Blaine Davis - CFO Carsten Brunn - CEO, President & Director Peter Traber - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Securities Kristen Kluska - Cantor Fitzgerald John Newman - Canaccord Genuity Dipesh Patel - H.C. Wainwright & Co. Uy Ear - Mizuho Securities Gil Blum - Needham & Company Operator Good morning, and thank you for joining the Selecta Biosciences First Quarter 2023 Earnings Call.
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
GlobeNewsWire
28 апр 2023 г. в 16:05
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.
4 Hot Penny Stocks To Watch With News This Week
PennyStocks
21 мар 2023 г. в 09:01
Penny stocks to watch this week. The post 4 Hot Penny Stocks To Watch With News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Selecta Biosciences, Inc. (SELB) Q4 2022 Earnings Call Transcript
Seeking Alpha
02 мар 2023 г. в 15:16
Selecta Biosciences, Inc. (NASDAQ:SELB ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Blaine Davis - Chief Financial Officer Carsten Brunn - President, Chief Executive Officer & Director Peter Traber - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Securities Kristen Kluska - Cantor Fitzgerald John Newman - Canaccord Genuity Yun Zhong - BTIG Gil Blum - Needham & Company Tiffany Marchell - William Blair Boobalan Pachaiyappan - H.C. Wainwright Uy Ear - Mizuho Operator Good morning, and welcome to the Selecta Bio Fourth Quarter 2022 Earnings Release Conference Call.
Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week
PennyStocks
13 февр 2023 г. в 14:47
Penny stocks under $3 to watch this week. The post Best Penny Stocks To Buy?